Growth for the firm's core lab and pathology lab businesses was offset by a decline in molecular diagnostics and near patient care in the first nine months of the year.

The firm said it will develop a test for use at home and at the point of care to aid the diagnosis of syphilis and distinguish between active and past infections.

The Houston-based firm is set to scale up its Flu/Covid test manufacturing for the current respiratory virus season.

Quest has developed a multi-target molecular test for avian influenza A H5 virus that it plans to make available by the end of October.